Specific Diagnostics to Present at the 41st Annual Canaccord Genuity Growth Conference | New
MOUNTAIN VIEW, CALIFORNIA., June 15, 2021 / PRNewswire-PRWeb / – Specific Diagnostics to Present at the 41st Annual Canaccord Genuity Growth Conference, to be held August 10-12 of this year.
For the past 40 years, this annual event has brought together institutional investors from around the world with some of the best and most promising growth companies in technology. Last year, Canaccord Genuity’s event hosted more than 530 public and private companies and more than 2,900 attendees, made up of a wide variety of institutional and private investors.
“We look forward to participating in Canaccord’s 2021 Growth Companies Conference,” said Dr. Paul A. Rhodes, CEO of Specific. “With CE mark registration and our launch of the AST Rapid Reveal System in Europe, and with clinical trials in the United States ongoing, Specific has a lot to share with the diagnostic investment community. “
Clinicians often wait 2 days after a positive blood culture sample is available to receive the AST results required to guide effective antibiotic therapy, which identification results alone do not provide. This delay leads to overuse of expensive broad-spectrum antibiotic therapy and can be life-threatening. The result of the AST on the same shift of Specific allows either a rapid de-escalation to targeted and less expensive therapy, eliminating harmful disturbances to the microbiome, or an immediate escalation to a drug of last resort in the increasing case. most common where multidrug resistant infection is present, life saving.
Reveal’s low cost, high throughput, large menu, and small footprint are all suited for large-scale adoption. Its modular system design ensures no single point of failure, 100% uptime and gradual adoption by hospitals of all sizes, while the unique Reveal Dashboard ™ provides the lab with easy-to-use real-time tools. to monitor infection and resistance trends.
“This is our first presentation to the investment community since announcing our clinical trials in the United States,” said Dr. Rhodes, “and given all the recent activity in the area of rapid diagnostics infectious diseases, we anticipate and look forward to a robust information exchange with investors evaluating companies in this dynamic and rapidly growing market. ”
Specific Diagnostics has developed in vitro diagnostic systems based on a unique and patented metabolomic signature technology that allows rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new ability to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as dilutions of isolates. Specific is based in Mountain View, California.
For press inquiries, please contact: [email protected]
Jeffrey Holman, Specific diagnostics, 3176179153, [email protected]